Drugs / [18F]AlF-OC
[18F]AlF-OC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07104487 | Mar 2025 → Sep 2026 overdue | atherosclerotic cardiovascular disease, stroke disorder | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]AlF-OC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07104487 ↗ |
| Known as | Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide | “Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with...” NCT07104487 ↗ |
| Modality | Diagnostic / imaging agent | “molecular imaging with \[18F\]AlF-OC PET/MRI” NCT07104487 ↗ |